SCHEMBL3450041

SCHEMBL3450041

CCOC(=O)C1=Cc2ccc(O)cc2OCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.43
CA1 P00915 4/20 0.43
CA2 P00918 4/20 0.43
CA7 P43166 4/20 0.43
CA9 Q16790 4/20 0.43
CA14 Q9ULX7 4/20 0.43
NR1H4 Q96RI1 1/20 0.42
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
MAPK1 P28482 2/20 0.40
GAA P10253 2/20 0.40
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
CLK1 P49759 1/20 0.39
MIF P14174 1/20 0.39
PFKFB3 Q16875 1/20 0.39
AKR1B1 P15121 1/20 0.39
MAPT P10636 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7385872 0.86 CA12 (0.47) CA12CA2CA9MAOBMAPK1
SCHEMBL5546808 0.83 ALOX5 (0.48) CA12CA9MAOAMAOBNPC1
SCHEMBL14402403 0.82 ALOX5 (0.41) CA12CA9NR1H4MAOBMAPK1
SCHEMBL3452161 0.81 MAOB (0.52) ESR1MAOAMAOBNPC1RAB9A
SCHEMBL7382482 0.81 CA12 (0.47) CA12CA9MAPK1NPC1RAB9A
SCHEMBL7388942 0.80 ALOX5 (0.43) MAPK1NPC1RAB9ACLK1MAPT
SCHEMBL7380758 0.79 CA12 (0.47) CA12CA2CA9MAOBMAPK1
SCHEMBL7382857 0.79 MAPT (0.43) MAOAMAPK1GAANPC1RAB9A
SCHEMBL7697013 0.79 NPC1 (0.41) MAPK1NPC1RAB9ACLK1MAPT
SCHEMBL5209415 0.79 CCR2 (0.43) MAOBMAPK1NPC1RAB9ACLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820837-B2 ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820837-B2 ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820837-B2 ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-20060258722-A1 Condensed ring compound TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) 2006-11-16 US disclosed
EP-1630152-A1 CONDENSED RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2006-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258722-A1 Condensed ring compound GPR119, GLP1R, GCGR CA12 3921/4885CA1 2870/4885CA2 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.